Alberto Giovanni LeoneChelsea and Westminster Hospital NHS Foundation Trust, shared a post on LinkedIn about his recent paper published in ESMO Open:

“In PD-L1 ‘low’ HER-2 negative gastroesophageal adenocarcinoma, the benefit of first-line ICI is modest.

Alternative therapeutic options such as zolbetuximab in Claudin18.2-positive disease must be taken into account.”

“Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups”

Authors: Alberto Giovanni Leone, Khi Yung Fong, Elizabeth Smyth, Joseph Zhao, Filippo Pietrantonio et al.

Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma

Alberto Giovanni Leone is an HIV/Oncology Fellow at Chelsea and Westminster Hospital NHS Foundation Trust. He also serves as a Medical Oncology Resident at the IRCCS Foundation National Cancer Institute of Milan.